MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals
MacroGenics will sell its GMP drug substance manufacturing operations to Bora Pharmaceuticals for a $122.5 million upfront payment, transferring its Rockville, Maryland facility and approximately 140 employees to expand Bora’s North American biologics production. The deal, expected to close in Q3 2026, aligns with MacroGenics’ strategy to focus on advancing its cancer treatment pipeline while maintaining supply access through Bora.
MacroGenics, Inc., a clinical-stage biopharmaceutical company specializing in antibody-based cancer therapies, has agreed to sell its good manufacturing practice (GMP) drug substance manufacturing operations to Bora Pharmaceuticals Co., Ltd. for an upfront payment of $122.5 million. The transaction includes the transfer of MacroGenics’ Rockville, Maryland headquarters—an FDA-approved facility with an 11,000-liter capacity—and its Frederick, Maryland warehouse, along with approximately 140 employees. The deal supports MacroGenics’ strategy to prioritize its innovative pipeline and accelerate key value milestones in 2026. Eric Risser, CEO of MacroGenics, stated the transaction provides non-dilutive capital while allowing the company to maintain access to manufacturing capabilities for its internal pipeline through a supply arrangement with Bora. The sale excludes MacroGenics’ development and commercialization operations, which will continue under its ownership. Bora Pharmaceuticals, a global leader in pharmaceutical manufacturing, plans to integrate the Maryland site into its Bora Biologics division, expanding its North American biologics production alongside its existing Baltimore drug product operations. Bobby Sheng, Chairman of Bora, described the acquisition as a strategic move to strengthen Bora’s position as a full-service partner for biologics production. The transition will ensure continuity for MacroGenics’ existing CDMO clients and its own pipeline needs. The transaction is subject to customary closing conditions and is expected to finalize in the third quarter of 2026. Moelis & Company and Sidley Austin LLP advised MacroGenics, while Jones Day represented Bora. The deal follows MacroGenics’ 2025 announcement of strategic priorities focused on advancing its antibody-based cancer therapies.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.